

What is claimed is:

1. A method of treating an inflammatory disease by administrating a therapeutically effective amount of a PRO301, PRO362 or PRO245 antagonist, or fragment thereof.

5

2. The method of claim 1 wherein the antagonist is an antibody.

3. The method of claim 2 wherein the antibody is a monoclonal antibody.

10 4. The method of claim 3 wherein the antibody has non-human complementarity determining region (CDR) residues and contains human framework region (FR) residues.

5. The method of claim 4 wherein the antibody is a composition in admixture with a pharmaceutically acceptable carrier or excipient.

15

6. The method of claim 5 wherein the inflammatory disease is selected from the group consisting of: inflammatory bowel disease; systemic lupus erythematosus; rheumatoid arthritis; juvenile chronic arthritis; spondyloarthropathies; systemic sclerosis, for example, scleroderma; idiopathic inflammatory myopathies for example, dermatomyositis, polymyositis; Sjögren's syndrome; systemic vasculitis; sarcoidosis; autoimmune hemolytic anemia for example, immune pancytopenia, paroxysmal nocturnal hemoglobinuria; autoimmune thrombocytopenia, for example, idiopathic thrombocytopenic purpura, immune-mediated thrombocytopenia; thyroiditis, for example, Grave's disease, Hashimoto's thyroiditis, juvenile lymphocytic thyroiditis, atrophic thyroiditis; diabetes mellitus, immune-mediated renal disease, for example, glomerulonephritis, tubulointerstitial nephritis; demyelinating diseases of the central and peripheral nervous systems such as multiple sclerosis, 20 idiopathic polyneuropathy; hepatobiliary diseases such as infectious hepatitis such as hepatitis A, B, C, D, E and other nonhepatotropic viruses; autoimmune chronic active hepatitis; primary biliary cirrhosis; granulomatous hepatitis; and sclerosing cholangitis; inflammatory and fibrotic lung diseases (e.g., cystic fibrosis); gluten-sensitive enteropathy; Whipple's disease; autoimmune or immune-mediated skin diseases including bullous skin diseases, erythema multiforme and contact dermatitis, psoriasis; allergic diseases of the lung such as eosinophilic 25 pneumonias, idiopathic pulmonary fibrosis and hypersensitivity pneumonitis, transplantation associated diseases including graft rejection and graft-versus-host disease.

30

7. A method for determining the presence of a PRO301, PRO362 or PRO245 polypeptide comprising exposing a cell suspected of containing the polypeptide to an anti-PRO301, anti-PRO362 or anti-245 antibody 35 and determining the binding of the antibody to the cell.

40

8. A method of diagnosing an inflammatory disease in a mammal, comprising detecting the level of expression of a gene encoding a PRO301, PRO362 or PRO245 (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher expression level in the test sample indicated the presence of an inflammatory disease in the mammal.

9. A method of diagnosing an inflammatory disease in a mammal, comprising: (a) contacting an anti-PRO301, anti-PRO362 or anti-PRO245 antibody with a test sample of tissue culture cells obtained from the mammal, and (b) detecting the formation of a complex between the antibody and the PRO301, PRO362 or PRO245 polypeptide.
- 5
10. A method of for inhibiting the growth of tumor cells comprising exposing a cell which overexpresses a PRO301, PRO362 or PRO245 polypeptide to an effective amount of an agent inhibiting the expression and/or activity of the PRO301, PRO362 or PRO245 polypeptide, respectively.
- 10
11. The method of claim 10 wherein said agent is an anti-PRO301, anti-PRO362 or anti-PRO245 antibody.
12. The method of claim 11, wherein said tumor cells are further exposed to radiation treatment or a cytotoxic or chemotherapeutic agent.
- 15
13. A method diagnosing tumor in a mammal, comprising detecting the level of expression of a gene encoding a PRO301, PRO362 or PRO245 polypeptide (a) in a test sample of tissue cells obtained from the mammal, and (b) in a control sample of known normal tissue cells of the same cell type, wherein a higher expression level in the test sample indicates the presence of tumor in the mammal from the test tissue cells were obtained.
- 20
14. A method of diagnosing tumor in a mammal, comprising (a) contacting an anti-PRO301, anti-PRO362 or anti-PRO245 antibody with a test sample of tissue cells obtained from the mammal, and (b) detecting the formation of a complex between the anti-PRO301, anti-PRO362 or anti-PRO245 antibody and the PRO301, PRO362 or PRO245, respectively, in the test sample.
- 25
15. The method of claim 14 wherein said test sample is obtained from an individual suspected to have neoplastic cell growth or proliferation.
- 30
16. An isolated antibody which binds a PRO301 or PRO362 polypeptide.
17. The antibody of claim 16 which is a monoclonal antibody.
18. The antibody of claim 17 which contains non-human complementarity determining region (CDR) residues and human framework region (FR) residues.
- 35
19. The antibody of claim 18 which is labeled.
20. The antibody of claim 19 which is immobilized on a solid support
- 40

21. The antibody of claim 16 which is an antibody fragment, a single-chain antibody, or an anti-idiotypic antibody.
22. A composition comprising the antibody of claim 21 in admixture with a pharmaceutically-acceptable carrier.
23. The composition of claim 22 further comprising a second antibody or a cytotoxic or chemotherapeutic agent.
- 10 24. Isolated nucleic acid comprising DNA having at least a 95% sequence identity to (a) a DNA molecule encoding a PRO301 polypeptide comprising the sequence of amino acids 28 to 235 of Fig. 2 (SEQ ID NO: 1).
- 15 25. The isolated nucleic acid of claim 24 comprising DNA having at least a 95% sequence identity to (a) a DNA molecule encoding a PRO301 polypeptide comprising the sequence of amino acids 28 to 258 of Fig. 2 (SEQ ID NO: 1), or (b) the complement of the DNA molecule of (a).
- 20 26. The isolated nucleic acid of claim 25 comprising DNA having at least a 95% sequence identity to (a) a DNA molecule encoding a PRO301 polypeptide comprising the sequence of amino acids 28 to 299 of Fig. 2 (SEQ ID NO: 1), or (b) the complement of the DNA molecule of (a).
- 25 27. The isolated nucleic acid of claim 26 comprising DNA having at least a 95% sequence identity to (a) a DNA molecule encoding a PRO301 polypeptide comprising the sequence of amino acids 1 to 299 of Fig. 2 (SEQ ID NO: 1), or (b) the complement of the DNA molecule of (a).
- 30 28. The isolated nucleic acid of claim 24 comprising DNA encoding a PRO301 polypeptide having amino acid residues 28 to 235 of Fig. 2 (SEQ ID NO: 1).
29. The isolated nucleic acid of claim 28 comprising DNA encoding a PRO301 polypeptide having amino acid residues 28 to about 258 of Fig. 2 (SEQ ID NO: 1).
- 35 30. The isolated nucleic acid of claim 29 comprising DNA encoding a PRO301 polypeptide having amino acid residues 28 to 299 of Fig. 2 (SEQ ID NO: 1).
31. The isolated nucleic acid of claim 30 comprising DNA encoding a PRO301 polypeptide having amino acid residues 1 to 299 of Fig. 2 (SEQ ID NO: 1).
32. Isolated nucleic acid comprising DNA having at least 80% sequence identity to (a) a DNA molecule encoding a PRO362 polypeptide comprising the sequence of amino acid residues 1 to 321 of Figure 3 (SEQ ID NO: 2), or (b) the complement of the DNA molecule of (a).

33. The nucleic acid of Claim 32, wherein said DNA comprises the nucleotide sequence of SEQ ID NO: 8 or its complement.
34. The nucleic acid of Claim 32, wherein said DNA comprises nucleotides 119-1081 of the nucleotide sequence of SEQ ID NO: 7.
- 5 35. An isolated nucleic acid comprising DNA having at least a 95% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the cDNA in ATCC Deposit No. 209432 (designation: DNA40628-1216), or (b) the complement of the DNA molecule of (a).
- 10 36. The isolated nucleic acid of claim 35 comprising then PRO301 encoding sequence of the cDNA in ATCC deposit No. (designation: DNA40628-1216), or a sequence which hybridizes thereto under stringent conditions.
- 15 37. Isolated nucleic acid comprising DNA having at least an 80% sequence identity to (a) a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No.: 209620 (DNA45416-1251), or (b) the complement of the DNA molecule of (a).
- 20 38. The nucleic acid of Claim 37 which comprises a DNA molecule encoding the same mature polypeptide encoded by the human protein cDNA in ATCC Deposit No.: 209620 (DNA45416-1251).
- 25 39. Isolated nucleic acid comprising DNA having at least an 80% sequence identity to (a) a DNA molecule encoding a PRO362 polypeptide comprising the sequence of amino acid residues 1 to X of Figure 3 (SEQ ID NO: 2), or (b) the complement of the DNA molecule of (a), wherein X is any one of amino acid residues 271 to 280 of Figure 3 (SEQ ID NO: 2).
40. A process for producing PRO301, PRO362 or PRO245 polypeptides comprising culturing a host cell under conditions suitable for expression of PRO301, PRO362 or PRO245 and recovering PRO301, PRO362 or PRO245, respectively, from the cell culture.
- 30 41. Isolated native sequence PRO301 polypeptide comprising amino acid residues 28 to 235 of Fig. 2 (SEQ ID NO: 1).
- 35 42. The isolated native sequence PRO301 polypeptide of claim 41 further comprising amino acid residues 28 to about 258 of Fig. 2 (SEQ ID NO: 1).
43. The isolated native sequence PRO301 polypeptide of claim 42 further comprising amino acid residues 28 to 299 of Fig. 2 (SEQ ID NO: 1).
- 40 44. The isolated native sequence PRO301 polypeptide of claim 43 further comprising amino acid residues

1 to 299 of Fig. 2 (SEQ ID NO: 1).

45. Isolated native sequence PRO301 polypeptide encoded by the nucleic acid deposited under accession number ATCC 209432.

5

46. Isolated native sequence PRO362 polypeptide comprising amino acid residues 1 to 229 of Figure 3 (SEQ ID NO: 2).

47. Isolated PRO362 polypeptide comprising amino acids 1 to X of the amino acid sequence shown in Figure 3 (SEQ ID NO: 2), wherein X is any one or amino acids 271 to 280.

10 48. Isolated PRO362 polypeptide encoded by the cDNA insert of the vector deposited as ATCC Accession No. 209432 (DNA45416-1251).